東陽光(600673.SH):阿立哌唑片獲批上市
格隆匯2月25日丨東陽光(600673.SH)公佈,公司控股子公司東莞市陽之康醫藥有限責任公司於近日收到國家藥監局核准簽發的阿立哌唑片《藥品註冊證書》。
阿立哌唑用於治療精神分裂症,屬於第二代抗精神病藥物。目前認為阿立哌唑的作用機制是通過D2受體和5-HT1A受體的部分激動作用及5-HT2A受體的拮抗作用的介導而產生。與第一代抗精神病藥相比,阿立哌唑副作用小及服用簡單,增加了服藥依從性,使得病情更加穩定。目前,阿立哌唑片的生產企業主要有浙江大冢製藥有限公司、浙江華海藥業股份有限公司等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.